On September 25, 2026, Craig-Hallum initiated coverage of TELA Bio (NASDAQGM: TELA) with a “Buy” recommendation. That same day, TELA Bio’s stock closed at $1.28, marking a 2.40% increase from $1.25 one week earlier and an impressive 82.86% jump from $0.70 a month prior.
The consensus target price for TELA Bio stands at a mean of $2.14, suggesting a potential upside of 67.34%. In its latest financial report dated August 10, 2026, TELA Bio reported revenues of $19.29 million, falling short of the estimated $20.41 million and an EPS of -0.2 compared to an estimate of -0.1818. Overall, analyst sentiment remains stable, with 81.8% of recommendations rated as positive as of September 1, 2026.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
